Alnylam Pharmaceuticals is a biopharmaceutical company engaged in developing novel therapeutics based on RNA interference (RNAi). The company is at the helm of translating RNAi into a new class of innovative medicines, with a core focus on RNAi therapeutics for treating genetically defined diseases. As part of its “Alnylam 5×15” strategy, Alnylam plans to have five RNAi therapeutic products for genetically defined diseases in clinical development by the end of 2015. For more information, visit the company’s Web site at www.alnylam.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: